학술논문

BRAF polymorphisms and the risk of ovarian cancer of low malignant potential
Document Type
article
Source
Gynecologic Oncology. 97(3)
Subject
Biomedical and Clinical Sciences
Oncology and Carcinogenesis
Rare Diseases
Ovarian Cancer
Human Genome
Clinical Research
Cancer
Prevention
Genetics
Aetiology
2.1 Biological and endogenous factors
Adult
Aged
Aged
80 and over
Case-Control Studies
Cystadenocarcinoma
Serous
Female
Genetic Predisposition to Disease
Haplotypes
Humans
Middle Aged
Ovarian Neoplasms
Polymorphism
Single Nucleotide
Proto-Oncogene Proteins B-raf
BRAF
susceptibility
polymorphism
ovarian cancer
low malignant potential
LMP
Paediatrics and Reproductive Medicine
Oncology & Carcinogenesis
Clinical sciences
Oncology and carcinogenesis
Reproductive medicine
Language
Abstract
ObjectiveThe object of this study was to test the hypothesis that BRAF is a low-risk susceptibility gene for low malignant potential (LMP) ovarian cancer. A recent study of the relationship between BRAF polymorphisms and malignant melanoma identified strong linkage disequilibrium across the BRAF gene with one of the three most common haplotypes (haplotype C) having a population attributable risk of approximately 1.6%. We therefore hypothesized that the same BRAF haplotype may confer an increased risk of serous ovarian tumors of low malignant potential.MethodsWe genotyped 383 cases of LMP ovarian cancer, including 234 of serous histology, and 987 controls for seven SNPs, representative of the most common BRAF gene haplotypes, using MALDI-TOF mass spectrometry.ResultsHaplotype information was obtained for 369 LMP ovarian cancer cases and 983 healthy controls. None of the haplotypes were found to be associated with risk of LMP ovarian cancer (OR for haplotype C 0.81, 95% CI = 0.54-1.22), or with the risk of serous LMP ovarian cancer (OR for haplotype C 0.90, 95% CI = 0.56-1.45).ConclusionWe found no evidence to suggest that BRAF is a low-risk LMP ovarian cancer susceptibility gene.